Background: Diabetic neuropathy is a common complication in diabetes, with patients typically experiencing diverse sensory symptoms including dysesthesias in the feet and usually accompanied by sleep disturbance. There is still no comprehensive understanding of the underlying biologic processes responsible for diabetic neuropathic pain. Thus, the current symptomatic therapy remains unsatisfactory. Recent experimental evidence suggests that botulinum toxin type A (BoNT/A) may not only inhibit the release of acetylcholine at the neuromuscular junctions, but also modulate afferent sensory fiber firing, thereby relieving neuropathic pain.
Neuropathic pain is one of the most common complications of diabetic neuropathy. 1 More than 25% of patients with type 2 diabetes have neuropathic pain syndromes. 2 The pain, usually attacking the distal extremities, results in disturbed sleep and diminished quality of life. 2 Unlike nociceptive pain, which is related to tissue damage from many types of irritants, neuropathic pain arises from damage to the peripheral nervous system or CNS. Both peripheral and central sensitization processes are involved in the pathophysiology of neuropathic pain. 3, 4 Alterations to the sympathetic nerve terminals induced by inflammation from either neuropathy or tissue damage enhance the release of various pain substances into the peripheral nervous system. 5 The resultant damage to nervous afferent C-and A-delta fibers causes ectopic discharge, with the reduction in nociceptor thresholds and the resultant accumulation of sodium channels subse-quently being followed by neuroplasticity, alternation of the modulatory systems, and then central sensitization. 6 Although many symptomatic therapies are available for neuropathic pain, including antidepressants, anticonvulsants, and opioids, as well as some novel strategies, many of these remain unsatisfactory. 7 A small number of patients do not tolerate the adverse events.
Botulinum toxin has been found to suppress both nociceptor sensitization and neuropathic pain such as trigeminal neuralgia and carpal tunnel syndrome. [8] [9] [10] In this study, we evaluate the effects of intradermal, rather than intramuscular, BoNT/A injections on pain symptoms in patients with diabetic neuropathic pain.
METHODS This is a randomized double-blind crossover trial. The study design is shown in the CONSORT flowchart (figure 1). 11, 12 The Clinical Trial Registration number is NCT00336349 (www.clinicaltrials.gov).
Patients.
A total of 20 patients with type 2 diabetes were recruited for this study. Each of these patients was required to have a minimum history of 3 years of diabetes mellitus and neuropathic pain in both feet. There were also prerequisites that the medication for neuropathic pain had not been changed within the previous 1-month period and that the symptoms were stationary.
The symptoms included bilateral pedal paresthesia and stocking distribution of tingling pain, burning, sharp shooting pain, and pruritic pain, which would fit the diagnostic criteria for neuropathic pain based on the DN4 questionnaire; furthermore, nerve conduction velocity (NCV) examinations should show polyneuropathy patterns. DN4 is a clinician-administered questionnaire. It consists of both sensory descriptors by interview and signs based on bedside sensory examination. It has a high level of sensitivity and specificity in discriminating neuropathic from nociceptive and somatic pain, and can help in the correct detection of neuropathic pain. 13 The patients should have four or more items positive among the 10 items of the DN4 questionnaire. The NCV examination should show either reduction of amplitude or slowing down of conduction velocity in peroneal, tibial, or sural nerve. The cutoff values of NCV examination were 40 m/sec for motor NCV and 2 mV for compound motor action potential (CMAP) and 2 V for sensory action potential (SAP). The visual analog scale (VAS) of all patients at entry time was Ͼ4.0. No alterations were made to the prescribed medications for neuropathic pain during the study period.
The exclusion criteria included peripheral arterial occlusion disease, diagnosed based on sonography with ankle-brachial (A/B) ratios below 1.0, any infection at the injection site, and any lumbar-sacral radiculopathy based upon clinical presentation, neurologic examination, and lumbar spine x-ray films. Patients with motor deficit were excluded. The other possible confounding causes of painful neuropathy, such as alcoholism and renal function impairment, were also excluded. This study was approved by the Intra-institute Research Board at Taipei Medical University Hospital, with each of the participants providing written informed consent.
Intradermal BoNT/A injection.
The patients were initially selected at random to receive either BoNT/A or normal saline injections on both feet. Twelve weeks later, each participant was crossed over to received a second injection with the other treatment, saline or BoNT/A. The injections were distributed across the dorsum of the foot, in a grid distribution pattern covering a total of 12 (3 ϫ 4) sites ( figure 2A ). The distribution of these sites was such that the distance between them was approximately equal. To keep the study blind, the preparation of saline and BoNT/A was performed by an independent study nurse, who did not participate in the interview of participants.
The patients were first asked to clean their feet; then 2% Xylocaine jelly was applied as a topical anesthetic for 3 minutes. After the Xylocaine jelly was removed with water, the feet were thoroughly cleansed with an antiseptic solution of 75% alcohol-beta iodine and three subsequent applications of 75% alcohol.
Fifty units of BoNT/A in 1.2 mL 0.9% saline were then administered intradermally into each foot, with each injection comprising approximately 4 U BoNT/A (BOTOX), 0.10 mL, using a 5/16-inch, 30-g needle. The 0.9% saline injections were performed in an identical manner ( figure 2A ).
Outcome assessment. The VAS, the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI), and the Short Form-36 (SF-36) quality-of-life questionnaire were performed at 1-week, 4-week, 8-week, and 12-week intervals after the initial injection. 14, 15 For VAS measurement, the study nurse asked the patients to point out the current pain severity during the last day on a rule with 0.0 -10.0 scales (0.0 ϭ no pain, 10.0 ϭ unbear- As compared to the placebo group, there were significant reductions in VAS in the BoNT/A group for each of these timepoints, p ϭ 0.014 at 4 weeks, 0.039 at 8 weeks, and 0.024 at 12 weeks. In a comparison between the two groups for each of these timepoints, the differences between the groups achieved significance at the 4-, 8-, and 12week stages. The BoNT/A treatment began to show a trend toward improving after just 1 week, with the effect ultimately lasting for 12 weeks. Within the BoNT/A treatment group, 44.4% (8/18) experienced good responses (a reduction in VAS of Ն3) within 3 months after the initial injection, whereas no good responses were found in the placebo group, p Ͻ 0.005 (table 2 and figure 2B ).
Reduction in total scores for CPSQI. The scores for the CPSQI indicated that most of the participants were poor sleepers (CPSQI Ն7); however, the difference in the improvement in sleep quality between the BoNT/A treatment group and the placebo group reached significance (p Ͻ 0.05) only 4 weeks after A comparison was undertaken of the changes in the scores for the physical and mental components of the SF-36 quality-of-life questionnaire between the two groups at the same timepoints; however, there were no significant differences or improvements found in these components during the period of our study (table 3) .
DISCUSSION This pilot study of intradermal
BoNT/A injections for diabetic neuropathic pain suggests a potential role for intradermal BoNT/A as a potentially effective treatment. Although it was not the case for every patient, it was found in this doubleblind crossover study that BoNT/A did significantly improve the mean VAS of pain at the 4-week stage after the injections for a period lasting at least 12 weeks. On the other hand, the relatively modest decrease in VAS values among the saline group did not reach significance and it could be a placebo effect. Furthermore, there were no major complications arising as a result of these injections.
In several preclinical models, BoNT/A effectively blocks the release of calcitonin gene-related peptide, substance P, and glutamate from afferent nerve ter-minals. 16, 17 Extracellular ATP is implicated in a considerable number of sensory processes, including pain. BoNT/A has been reported to block an ATP receptor, P2X 3 , which is almost exclusively expressed in the sensory neurons. Furthermore, evidence shows that this receptor plays a specific role in nociception, with the activation of P2X 3 by ATP leading to a much stronger nociceptive effect in inflamed tissue. 18, 19 BoNT/A also effectively blocks the translocation of the pain-related transient receptor potential channel receptor (TRPV1) in peripheral nociceptor terminals. 20 The VAS scores before treatment (week 0) were a little lower in the placebo group than in BoNT/A. This might be attributed to the impact of BoNT/A on a few participants who took BoNT/A therapy first and the effectiveness persisted for over 12 weeks when they took placebo therapy. Therefore, it is possible that the VAS at 1 and 4 weeks might be skewed toward showing a lesser difference between the groups. Our study design only surveys the VAS at single timepoints instead of averaged pain severity within a specific period. This made the question easier to understand for the elderly participants but this study design could lose the information of some time periods.
The study design referred to the previous experience of BoNT/A, with the mean effective dosage of BoNT/A for trigeminal neuralgia being 3.17-3.31 units/cm 2 . 9 Since the area of each dorsal foot is over 100 cm 2 for most people, the dosage adopted for this trial of diabetic neuropathic pain was below 0.5 units/cm 2 , which is much lower than that for trigeminal neuralgia. Whether increase of dosage could enhance the efficacy of BoNT/A for diabetic neuropathic pain is uncertain. Clearly, however, the optimal dosage for diabetic neuropathic pain will require further investigation.
Most of the reports on BoNT/A injections for dystonia indicate that the respective onset and effectiveness duration were about 1 week and 3 months. In the present study, the onset occurred later than 1 week after the injections, with the effectiveness possibly lasting for at least 3 months; therefore, the course of intradermal BoNT/A injections for diabetic neuropathic pain is clearly similar to, but not the same as, the course of BoNT/A injections for dystonia or trigeminal neuralgia. Thus, further comprehensive trials are clearly warranted in order to determine the onset and effectiveness duration.
It is already well recognized that BoNT/A inhibits the release of the neurotransmitter-containing vesicles from the nerve ending into the synapse. In a formalin-induced pain study, the antinociceptive effect of BoNT/A was found to have an association with the inhibition of glutamate release from the primary afferent terminals. 21 Glutamate is also involved in the induction and maintenance of central sensitization of pain by exerting its postsynaptic effect via the NMDA receptors. 22 Those raise the possibility of potential central effects of BoNT/A. There are de-bates that BoNT/A injection at peripheral sites results in alternation of central modulatory system then changes the pain severity over the sites without BoNT/A injection. To avoid the confusion of central effects of BoNT/A, our study design is BoNT/A or saline injection in both feet simultaneously instead of injection of BoNT/A and saline separately for comparison of each other in the mean time. This study is unable to approach the issue of central effects of BoNT/A. Botulinum toxin has been used in various types of pain therapy, including migraine, myofascial pain syndrome, plantar fasciitis, arthritis, and trigeminal neuralgia. 9, [23] [24] [25] [26] These trials have succeeded in extending the field of traditional pain therapy, particularly for the unsatisfactory treatment of neuropathic pain. Since diabetic neuropathic pain is associated with sleep impairment, it may be an important factor in life and sleep quality among diabetic patients. Sleep disturbance is therefore also an issue of importance in the care of diabetic patients. 27 Our results raised a possibility of improvement of sleep quality by BoNT/A therapy. The treatment significantly improved sleep quality only at the 4-week timepoint, although there were trends toward improvement at the other timepoints (table 3) . However, the impact on sleep quality from improvement in neuropathic pain needs further investigation because the results of improvement of sleep quality did not parallel with neuropathic pain at other timepoints. In this study, BoNT/A injections failed to improve life quality surveyed by SF-36 in physical and mental domains. This result might reflect the complexity of contributory factors in life quality. Improvement of neuropathic pain induced by BoNT/A injections might be not significant enough on alteration of life quality. What diabetic patients consider in measuring their life quality needs further investigation. This trial indicates that intradermal BoNT/A injections are an effective and safe method of relieving diabetic neuropathic pain in the feet. The detailed underlying mechanisms, optimal dosage, and precise course of therapy require further evaluation.
